TAIPEI, Aug. 21, 2025 /PRNewswire/ — WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launch two new products.
Chairman of Synmosa biopharma group, Peter Lin (Second from the left), and Chiarman of WCC biomedical, Dr. TJ Liu (Second to the right) celebrate the sucess debut of WCC biomedical.
To explore WINMAP™ technology for vaccines and pharmaceuticals, join WCC at the Total Store Expo on August 23–25 in San Diego, CA: Booth # 900
Following a successful debut at BIO Asia in Taiwan (July 23–27), WCC will offer demonstrations of its new products at TSE, allowing attendees to witness the benefits of microneedle-based patch solutions for themselves. Its two new MAP products are a homeopathic pain-relief patch and a herbal MACA patch, both available via the standard dissolvable WINMAP platform. WCC will exhibit at TSE alongside its key partner and investor, Synmosa Group, a leading specialty pharmaceutical company in Taiwan.
“Our WINMAP™ platform sets a new standard for producing microneedles — with an unprecedented combination of high-precision molds, accurate drug loading, and efficient, scalable mass production,” remarked Ta-Jo Liu, Chairman and CEO of WCC Biomedical. “With this first-in-class platform, we aim to demonstrate how MAPs can expand possibilities for nutrition and pharmaceuticals with needle-free, painless delivery.”
Precision, scale, and consistency with WINMAP™
A next-generation drug delivery system, WINMAP™ uses micrometer-scale needles made of medical-grade polymers to deliver active ingredients painlessly through the skin —without the need for any kind of injection. The technology leverages a combination of penetration, dissolution, diffusion, and formulation to deliver active ingredients more effectively than traditional transdermal patches or topical creams.
Key features include:
- Needle-free, pain-free delivery: Eliminates the need for syringes, reducing the risk of infection and minimizing patient discomfort.
- Scalable production: WCC’s automated manufacturing lines can produce over 10 million MAPs annually with high yield and consistency.
- Precision Loading and Coating (PLC) process: Provides customizable molding, accurate dosing, smart drying, and proprietary coating technologies.
Advanced formulation databases: The Microneedles Material Database (MMDB) and Microneedles Formulation Database (MFDB) support rapid development of MAPs with tailored release profiles, from rapid onset to controlled delivery.
Video link: https://youtu.be/uZpOmihUX90
Advancing health equity
In addition to improving patient comfort, MAPs are viable alternatives for low-resource areas where traditional injection-based therapies are impractical. At a time when medical aid for the developing world is receding, solutions like WINMAP™ have significant potential as high-impact solutions for advancing global health equity.
For more information, please visit: https://wccbiomedical.com/en/
About WCC Biomedical
Founded in 2014 and headquartered in Taiwan’s renowned Hsinchu Science Park, WCC Biomedical is a Taiwan-based biotech innovator specializing in novel drug delivery systems, focusing on microarray patches (MAPs). WCC combines precision polymer engineering, scalable manufacturing, and advanced formulation science to develop MAPs for healthcare, pharmaceutical, and beauty applications. With 14 patents from the US, Europe, and Japan and a growing global footprint, WCC is committed to transforming how medicines and vaccines are delivered—painlessly, efficiently, and equitably.
